Quick Answer
ACADIA PHARMACEUTICALS INC reported Operating Income Loss of $104.81 million for the year ending 2025.
- ACADIA PHARMACEUTICALS INC showed a decrease of -54.6% in Operating Income Loss from 2024 to 2025.
- This data is from ACADIA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), ACADIA PHARMACEUTICALS INC's Operating Income Loss has grown by 330.5%.
- Historical annual values: Fiscal year 2025: $104.81 million | Fiscal year 2024: $230.79 million | Fiscal year 2023: -$73.38 million | Fiscal year 2022: -$223.60 million | Fiscal year 2021: -$170.44 million | Fiscal year 2020: -$286.59 million | Fiscal year 2019: -$246.55 million | Fiscal year 2018: -$247.44 million | Fiscal year 2017: -$292.41 million | Fiscal year 2016: -$272.82 million | Fiscal year 2015: -$164.61 million | Fiscal year 2014: -$93.23 million | Fiscal year 2013: -$38.30 million | Fiscal year 2012: -$20.89 million | Fiscal year 2011: -$22.85 million | Fiscal year 2010: $15.09 million | Fiscal year 2009: -$45.47 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: